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(57) ABSTRACT 
The invention relates to the use of nicotinic acid alkyl esters, 
especially myristyl nicotinate, to inhibit side effects associ-
ated with retinoic acid therapy. Also a part of the invention 
is a method for improving skin cell differentiation by admin-
istering the nicotinic acid alkyl ester in an amount sufficient 
to increase expression of caspase 14 and filaggrin. Deficien-
cies in expression of these molecules can be treated in this 
way as well. 
7 Claims, No Drawings 
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METHOD FOR ALLEVIATING SIDE 
EFFECTS OF RETINOIC ACID THERAPY 
AND/OR IMPROVING EFFICACY WITHOUT 
INTERFERING WITH EFFICACY 
2 
eration in the basal and/or lower spinous layers of the 
epidermis. Eichner, et al., Br J Dermatol 1996; 135: 687-95. 
Retinoids also can lighten hyperpigmented skin, reduce 
tyrosinase activity in cultured melanocytic cells (Hoa!, et al., 
RELATED APPLICATION 
This application is a 371 application from PCT/US2008/ 
002605 filed Feb. 27, 2008, which claims priority of Pro-
visional application Ser. No. 60/903,937 filed Feb. 28, 2007, 
and incorporated by reference in their entirety. 
5 Cancer Res 1982; 42: 5191-5; Kang, et al., Am J Clin 
Dermatol 2005; 6: 245-53), inhibit proliferation and lipid 
synthesis, and alter keratin expression in cultured human 
sebocytes. Zouboulis, et al., J Invest Dermatol 1991; 96: 
792-7. In the dermis, effects include increased fibroblast 
FIELD OF THE INVENTION 
10 proliferation (Varani, et al., supra), increased collagen pro-
duction (Griffiths, et al., N Engl J Med 1993; 329: 530-5), 
and reduced extracellular matrix degradation (Fisher and 
Voorhees, supra). 
The degradation of collagen in the dermis is a major factor 
The invention relates to the use of niacin derivatives to 
alleviate side effects resulting from retinoic acid therapy 
and/or improving efficacy without interfering with efficacy 
of retinoic acid therapy. More particularly, niacin deriva-
tives, such as straight chain nicotinic acid alkyl esters, 
myristyl nicotinate in particular, alleviate side effects from 
retinoic acid therapy such as, but not exclusively, tightness/ 
dryness, stinging, burning, and tingling, as discussed infra. 
Also a feature of the invention is the improvement of skin 
cell differentiation by increasing expression of caspase-14 
and filaggrin. 
15 in the formation of skin wrinkles. Prolonged use of retinoic 
acid significantly increases collagen matrix deposition in 
dermal repair zones and this effect appears to be responsible 
for the wrinkle reduction that accompanies retinoic acid 
treatment of photodamaged skin. (Cho, et al., supra; Kang, 
20 et al., supra). 
While retinoic acid provides multiple benefits to pho-
todamaged skin (Kang, et al., supra), it is frequently accom-
panied by significant skin irritation that limits compliance 
with therapy. Lowe, et al., J Cosmet Laser Ther 2004; 6: 
BACKGROUND OF THE INVENTION 
25 79-85. The most commonly reported retinoic acid treatment-
related adverse effects are irritation, dryness, peeling, ery-
thema, and a sensation of burning on the skin. Lowe, et al., 
supra. These side effects often result in discontinuation of 
Retinoids, the natural metabolites and synthetic analogues 
of vitamin A (retinal), are important regulators of skin 30 
function. Fisher, et al., FasebJ 1996; 10: 1002-13. All-trans-
retinoic acid (vitamin A acid), the major naturally occurring 
biologically active retinoid, has been a focus of research for 
possible use in topical treatments for photodamaged skin, 
for many years. In 1986, it was reported that retinoic acid 35 
could produce smoother, less wrinkled, and less pigmented 
skin after a few months of treatment. Kligman et al., J Am 
Acad Dermatol 1986; 15: 836-59. 
Long-term exposure of skin to sunlight leads to a series of 
progressive changes that range from loss of skin texture and 40 
tone to thinning of the epidermis and stratum comeum 
(Gilchrest, Br J Dermatol 1996; 135: 867-75), flattening of 
the dermal-epidermal junction (Benedetto, Clin Dermatol 
1998; 16: 129-3 9 ), generation of areas of hyperpigmentation 
(Gilchrest, supra), wrinkles, and accumulation of keratino- 45 
cytes with atypical morphology that are likely precursors to 
actinic keratoses and non melanoma skin cancers (Cho, et 
al., J Am Acad Dermatol 2005; 53: 769-74; Lober, et al., J 
Am Acad Dermatol 2000; 43: 881-2). Photodamage occurs 
in both the epidermal and dermal compartments, where 50 
retinoids have been shown to have prominent pharmaco-
logical effects. Gendimenico, et al., Skin Pharmacol l 993; 6 
Suppl 1: 24-34; Varani, et al., J Invest Dermatol 2000; 114: 
480-6; Cho, et al., supra. In the epidermis of photodamaged 
skin, long-term topical retinoid therapy results in dose 55 
dependent increases in epidermal and granular layer thick-
ness, stratum corneum compaction, decreased melanin con-
tent and improvement of epidermal atypia. Fisher et al., 
supra; Cho, et al., supra; Olsen, et al., J Am Acad Dermatol 
1992; 26: 215-24; Machtinger, et al., Br J Dermatol 2004; 60 
151: 1245-52. In keratinocytes, retinoids induce prolifera-
tion, presumably mediated by epidermal growth factor 
receptor activation resulting in epidermal hyperplasia. Rit-
tie, et al., J Invest Dermatol 2006; 126: 732-9. 
Retinoic acid induced expression of keratins K6, Kl 6, and 65 
Kl 7, which are commonly expressed in hyperproliferative 
epidermal cells, indicates that retinoids increase cell prolif-
therapy. 
Hence, a method to diminish or eliminate the side effects 
associated with retinoic acid therapy is needed. 
The mechanisms that lead to retinoid side effects are still 
incompletely understood but retinoic acid therapy is known 
to impair stratum comeum barrier function as assessed by 
TEWL measurements. Tagami, et al., Br J Dermatol 1992; 
127: 470-5. Barrier impairment has been attributed to ret-
inoid-induced epidermal hyperplasia (Varani, et al., Arch 
Dermatol Res 2003; 295: 255-62) and to alteration of the 
terminal differentiation program (Fisher, et al., supra). Ery-
thema, which reflects the production of epidermal cytokines 
such as IL-1, may result from retinoid-stimulated keratino-
cyte proliferation directly or as a consequence of epidermal 
barrier impairment. Wood, et al., J Invest Dermatol 1996; 
106: 397-403; Blanton, etal.,ProcNatlAcadSci USA 1989; 
86: 1273-7. Retinoid-induced stratum corneum compaction 
(Olsen, et al., supra; Machtinger, et al., supra) is likely 
related to barrier impairment as stratum comeum thickness 
is a major determinant of barrier function (Ya-Xian, et al., 
Arch Dermatol Res 1999; 291: 555-9; de Jongh, et al., Br J 
Dermatol 2006; 154: 651-7). 
Niacin derivatives have been developed for optimal topi-
cal delivery of nicotinic acid to skin (Jacobson, et al., 
Developing Topical Prodrugs for Skin Cancer Prevention. 
In: Fundamentals of Cancer Prevention (Alberts D S, Hess, 
Lisa M., ed). Berlin Heidelberg: Springer-Verlag, 2005: 
139-60) and have been shown to enhance epidermal differ-
entiation in photodamaged skin, resulting in increased stra-
tum comeum and epidermal thickness and enhanced skin 
barrier function as assessed by decreased rates of TEWL. 
Jacobson, et al., Experimental Dermatology, in press. Niacin 
derivatives are also described in U.S. Pat. Nos. 6,337,065, 
6,677,361, 6,750,234 and 6,924,299, each of which is incor-
porated by reference in its entirety. 
One such niacin derivative is myristyl nicotinate, which 
was developed for optimal topical delivery of nicotinic acid 
to skin. Myristyl nicotinate has been shown to enhance 
epidermal differentiation in photodamaged skin, resulting in 
US 9,642,845 B2 
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increased stratum comeum and epidermal thickness and 
enhanced skin barrier function as assessed by decreased 
rates ofTEWL. Jacobson, et al., Experimental Dermatology, 
in press. 
Hence, it is an object of the present invention to treat the 
side effects caused by retinoic acid therapy with niacin 
derivatives. A further feature of the invention is the improve-
ment of skin cell differentiation via use of these niacin 
derivatives. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
EXAMPLE 1 
A clinical study was conducted to examined the combined 
use of retinoic acid therapy with myristyl nicotinate (MN), 
a lipophilic derivative of niacin that enhances skin barrier 
function, in subjects with mild to moderate facial photodam-
age. 
All subjects selected for the study were female, between 
the ages of 30 and 60, with a score of I to IV on the 
Fitzpatrick Skin Classification, mild to moderate photodam-
aged skin as defined by a modified Glogau Classification of 
I to II, and with presence of dyschromia on the face as 
determined by a woods light visual scan. 
The subjects were randomly assigned to one of three 
groups of 20 subjects each. One month prior to the initiation 
ofretinoic acid therapy, one of the groups (group 3) began 
to apply to the entire face, both night and morning, a 
formulation containing 5% myristyl nicotinate. Groups 1 
and 2 applied, in the same manner, a placebo formulation in 
which myristyl myristate replaced myristyl nicotinate. Upon 
initiation of retinoic acid therapy (baseline), group 1 (pla-
cebo/placebo+RA) continued to use the placebo formulation 
as above, group 2 (placebo/MN+RA) initiated use of the 5% 
myristyl nicotinate formulation and group 3 (MN/MN+RA) 
continued to use the 5% myristyl nicotinate formulation. 
Retinoic acid therapy involved a 0.025% concentration of 
the drug applied at night, immediately following application 
of the placebo or myristyl nicotinate containing formula-
tions. This strength of retinoic acid was chosen for this study 
as the subjects had mild to moderate photodamage. 
Subjects also were provided with mild liquid cleansers 
and sunscreen to use for facial cleansing and sun protection 
during the entire course of the study. Subjects applied the 
assigned test moisturizers [myristyl nicotinate (5%) or a 
placebo that contained myristyl myristrate replacing myri-
styl nicotinate] to their entire face twice per day after 
cleansing. During the usage phase of the study, subjects 
applied the retinoic acid formulation (0.025%) to their face 
after test moisturizer application once per day in the eve-
ning. 
The effects of the 5% myristyl nicotinate formulation on 
surrogate markers of skin barrier function, clinical and 
sensory irritation, and clinical efficacy associated with ret-
inoic acid use were evaluated. Periorbital skin biopsy 
samples were evaluated for stratum corneum thickness and 
rates oftransepidermal water loss (TEWL) were determined 
as surrogate measures of barrier function, tolerability was 
evaluated by clinical grading, and efficacy was assessed by 
clinical grading, patient self-assessment, and analysis of 
biopsy samples for epidermal thickness. 
4 
bility that stratum corneum compaction is one factor 
involved in the barrier impairment associated with retinoic 
acid therapy. 
Accordingly, periorbital biopsy samples obtained from 
5 study subjects were evaluated for stratum corneum thick-
ness. A board certified dermatologist collected a 2-mm 
punch biopsy from the right or left side of the face as 
determined by a randomization design of 7 randomly 
selected subjects from each group at baseline and after 12 
10 weeks of treatment. The punch biopsies were formalin-fixed, 
embedded in paraffin, cut into 5 µm cross-sections, mounted 
on slides, and stained with hematoxylin-eosin (H&E). 
Histological images were taken of the H&E stained cross 
sections with an Olympus inverted stage microscope using 
15 a !Ox by 0.45 Apochromat objective and a Nikon digital 
CCD camera. ImageJ image analysis software (NIH) was 
used to examine the images and perform measurements. 
Suprapapillary epidermal thickness (as measured from the 
top of the dermal papilla to the top of the granular layer) and 
20 stratum comeum thickness (as measured from the top of the 
granular layer to the top of the stratum corneum) were 
measured. For each specimen, five different sites were 
measured and the average was calculated. 
At baseline, the mean stratum comeum thickness value of 
25 the placebo/MN+RA group was slightly higher than the 
placebo/placebo+ RA group, although the difference was not 
statistically significant. The mean stratum comeum thick-
ness of the MN/MN+RA group, which had been treated for 
one month with 5% myristyl nicotinate, was higher than the 
30 other two groups, although the difference did not reach 
statistical significance at p<0.05. However, previous studies 
have shown that treatment of photodamaged skin with 5% 
myristyl nicotinate for 3 months results in an increase in 
stratum comeum thickness of more than 50%. Thus the 
35 approximately 11 % higher mean value of MN/MN+RA 
group compared to the mean values of the other groups 
agrees with the known effect of myristyl nicotinate. 
During the 12 weeks of retinoic acid therapy, the placebo/ 
placebo+RA group experienced a reduction in stratum cor-
40 neum thickness of approximately 24% (p=0.006 vs. base-
line), while concurrent use of myristyl nicotinate and 
retinoic acid did not result in a decrease in stratum comeum 
thickness. The difference in mean stratum comeum thick-
ness between the placebo/placebo+RA and placebo/MN+ 
45 RA group at 12 weeks of therapy was highly statistically 
significant (p=0.005). The difference between the MN/MN+ 
RA group and the placebo/placebo+RA group at 12 weeks 
also was highly statistically significant (p=0.003). These 
results show that concurrent or prior and concurrent use of 
50 myristyl nicotinate mitigates stratum comeum compaction 
associated with retinoic acid therapy. 
Determination of rates of TEWL provides a non-invasive 
assessment of relative skin barrier function. Hence, TEWL 
measurements were taken from the faces of study subjects 
55 and used as a surrogate marker of barrier function to 
compare placebo and myristyl nicotinate treated groups. For 
the TEWL measurements, the instruments required a speci-
fied temperature and humidity range for optimal function, 
thus subjects were required to equilibrate to ambient con-
60 ditions for at least 20 min prior to measurements. Tempera-
ture was maintained between 66 and 72° F. and relative 
Stratum corneum compaction typically accompanies ret-
inoic acid therapy and studies relating increased barrier 65 
function to an increased stratum corneum thickness (Ya-
Xian, et al., supra; de Jongh, et al., supra) raise the possi-
humidity maintained between 15 and 55%. A computer-
linked Dermalab instrument was used to measure TEWL at 
two points above the skin surface on the right cheeks of 
study subjects and the rate of water loss was calculated. 
Each TEWL measurement was averaged over a one-min 
measurement period. 
US 9,642,845 B2 
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The rates ofTEWL increased in the placebo/placebo+RA 
group by during the 12 week period approximately 45%, a 
value that was highly statistically significant (p<0.0001). 
The mean rates of TEWL also increased in the placebo/ 
MN+RA and MN/MN+RA groups, although the changes 5 
from baseline for these groups were not statistically signifi-
cant. The difference between the placebo/placebo+RA and 
MN/MN+RAgroups at 12 weeks (p=0.056) demonstrated a 
strong trend towards statistical significance. 
These results indicate that concurrent use of myristyl 10 
nicotinate mitigates barrier impairment and that prior use 
plus concurrent use provides greater barrier protection than 
concurrent use alone. 
Clinical Grading 
In order to assess both the tolerability and efficacy of 15 
retinoic acid therapy, subjects also were clinically graded on 
the right and/or left side of the face for efficacy/performance 
parameters and irritation/safety parameters at baseline, and 
weeks 2, 4, 8, and 12. 
The most severe parameters of tolerability such as seal- 20 
ing/peeling and degree of erythema were graded on 3-point 
clinical scale at weeks 2, 4, 8, and 12, and mean values were 
determined. The frequency of less severe parameters of 
tolerability typical of retinoic acid therapy (including tight-
ness/dryness, stinging, burning, and tingling) was also 25 
evaluated. 
6 
improvement (p=0.02) at 12 weeks in the MN/MN+RA 
group compared to the placebo/placebo+RA and a trend for 
greater improvement for the placebo/MN+RA compared to 
placebo/placebo+RA was observed that did not reach sta-
tistical significance at p<0.05. 
Study subjects also completed a self-assessment question-
naire at the completion of the study that related to their 
assessment of efficacy. This questionnaire requested study 
subjects to respond to questions with one of 5 choices 
(Strongly agree, agree, neither agree nor disagree, disagree, 
strongly disagree). In no case did subjects in the groups 
using myristyl nicotinate rate efficacy lower than subjects in 
the placebo/placebo+RA group and in four of the five 
questions a greater percentage of study subjects using myri-
styl nicotinate perceived improved efficacy compared to the 
placebo group. These results indicate that concurrent or prior 
and concurrent use of myristyl nicotinate did not interfere 
with retinoic acid efficacy and by some parameters resulted 
in improved efficacy. 
Since long term retinoid therapy is associated with an 
increase in epidermal thickness, changes in epidermal thick-
ness in each of the groups over the 12-week course of the 
retinoic acid therapy were also assessed. The mean values 
for the placebo/placebo+RA, placebo/MN+RA, and 
MN/MN+RA groups at the baseline were 37.9, 38.8, and 
39.3 µm, respectively. The mean epidermal thickness of the 
group receiving retinoic acid and the placebo cream 
decreased by approximately 5% over the 12 week study. The 
epidermal thickness of the group concurrently receiving 
myristyl nicotinate increased by approximately 3% and the 
group receiving myristyl nicotinate prior/concurrent with 
retinoic acid increased by approximately 10%. The differ-
ence between the placebo/placebo+RA and MN/MN+RA 
groups at 12 weeks was statistically significant (p=0.0007) 
The degree of scaling/peeling was very low in all groups 
and the degree of erythema also was relatively low, indicat-
ing an overall high degree of tolerance of the 0.025% 
concentration of retinoic acid and/or the regular use of a 30 
moisturizer twice per day prior to and during therapy. There 
were no statistically significant differences between placebo 
and myristyl nicotinate groups in either parameter, although 
the grading of erythema was consistently slightly higher in 
the myristyl nicotinate treated subjects. 
Despite the low levels of scaling/peeling or erythema, a 
significant frequency of less severe but commonly encoun-
tered side effects of retinoic acid were observed in the study. 
For these tolerability parameters, a consistent pattern was 
observed as concurrent use ofmyristyl nicotinate decreased 40 
the frequency of tightness/dryness, stinging, and burning, 
and prior and concurrent myristyl nicotinate use further 
reduced the frequency of each of these parameters. Although 
the frequency of tingling reported was quite low (2% ), the 
incidence of this side effect was reduced to zero for the 45 
MN/MN+RA group. 
35 while the difference between placebo/placebo and placebo/ 
MN+RA groups showed a trend but did not reach statistical 
significance at p<0.05. The difference between the placebo/ 
MN+RAand MN/MN+RAgroups at 12 weeks also reached 
In addition to the clinical grading, study subjects com-
pleted self-assessment questionnaires that solicited informa-
tion related to tolerability of the therapy. These self-assess-
ments paralleled the clinical grading in all cases where the 50 
same parameter was assessed. In total, the results show that 
use of myristyl nicotinate improved the tolerability of ret-
inoic acid therapy. 
Expert clinical grading, patient self-assessment, and 
analysis of biopsy samples for epidermal thickness were also 55 
used to examine the effect of myristyl nicotinate on the 
efficacy of retinoic acid therapy. 
Clinical grading involved evaluation of dyschromia, fine 
lines, shallow wrinkles, tactile roughness, and temple laxity 
as a function of treatment time (at weeks 2, 4, 8, and 12). 60 
Despite some differences in the degree of initial photodam-
age between the groups, similar rates of improvement for all 
three groups were observed for dyschromia, fine lines, and 
shallow wrinkles. This also was observed for tactile rough-
ness although scores for the MN/MN+RAgroup consistently 65 
showed greater improvement from weeks 4 to 12. Grading 
of temple laxity showed a statistically significant greater 
statistical significance (p=0.05). 
The results of clinical grading, self-assessment and epi-
dermal thickness determinations indicate that the efficacy of 
retinoic acid therapy was not negatively affected by myristyl 
nicotinate. Further, the results indicate that the use of 
myristyl nicotinate increased efficacy of retinoic acid 
therapy. 
EXAMPLE 2 
Caspase-14 has been shown to be a unique protease which 
controls maturation of the epidermis. This control results 
from proteolytic processing of filaggrin, a protein that is 
recognized as being involved in late stages of skin cell 
differentiation. The products of the action of caspase-14 on 
filaggrin prevent UVB photodamage, as well as water loss. 
See, e.g., Nicotera, et al., Nature Cell Biology 9:621-622 
(2007); Denecker, et al., Nature Cell Biology 9:666-674 
(2007), both of which are incorporated by reference. 
Rend!, et al., J. Investigative Dermatol 119: 1150-1155 
(2002), incorporated by reference, have shown that retinoids 
down regulate caspase 14. 
The interrelationships amongst caspase 14, filaggrin, and 
retinoids suggested that they might be impacted by myristyl 
nicotinate. 
To investigate this, the levels of expression of both 
caspase 14 and filaggrin were investigated in the groups of 
subjects referred to supra, (i.e., subjects who received pla-
cebo alone for one month, then placebo plus retinoic acid, 
US 9,642,845 B2 
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and those who received placebo only for one month and then 
myristyl nicotinate and retinoic acid during the treatment 
phase. 
An average increase of 5% in caspase 14 expression was 
found in subjects who received placebo plus retinoic acid for 5 
3 months, while subjects who received placebo, retinoic acid 
and myristyl nicotinate for 3 months showed a 24% increase 
in caspase 14 expression over the same period. 
With respect to filaggrin expression, subjects receiving 
placebo, myristyl nicotinate and retinoic acid showed an 10 
average increase of 13%, while subjects not treated with 
myristyl nicotinate showed no change. 
These results clearly establish a link between myristyl 
nicotinate and the beneficial effects of the interplay of 
caspase 14 and filaggrin, on skin cell differentiation, as 15 
discussed supra. 
8 
administration. For example, in the case of timed released 
application, "patches," such as the type used in timed release 
of nicotine, bandages, wraps, and so forth may be employed. 
The nicotinic acid ester is administered in an amount 
sufficient to alleviate a side effect of retinoic acid therapy. 
The dose used can and will vary. 
Another feature of the invention is the a method for 
improving mature skin cell differentiation, by administering 
an amount of a nicotinic acid alkyl ester, as described supra, 
in an amount sufficient to increase expression of caspase 14 
and filaggrin. Increased expression of these two molecules 
lead to increased interactions, which in turn leads to 
improvements in skin cell differentiation. Myristyl nicoti-
nate is especially preferred. 
Other aspects of the invention will be clear to the skilled 
artisan and need not be set forth herein. The terms and 
expressions which have been employed are used as terms of 
description and not of limitation, and there is no intention in 
the use of such terms and expressions of excluding any 
equivalents of the features shown and described or portions 
thereof, it being recognized that various modifications are 
possible within the scope of the invention. 
The invention claimed is: 
The foregoing description sets forth various features of 
the invention which include, inter alia, a method for allevi-
ating a side effect of retinoic acid therapy and/or improving 
efficacy and/or not interfering with efficacy in a patient 20 
receiving said therapy, by administering an amount of a 
nicotinic acid derivative, such as a nicotinic acid ester. 
Preferably, this is a nicotinic acid alkyl ester. Especially 
preferred are nicotinic acid alkyl esters, where the ester 
moiety contains from 10-18 carbon atoms. 25 1. A method for alleviating or preventing a side effect 
caused by retinoic acid without interfering with efficacy of 
said retinoic acid, comprising administering an amount of a 
nicotinic acid alkyl ester selected from the group consisting 
of myristyl nicotinate and palmityl nicotinate sufficient to 
The mode by which the nicotinic acid ester is adminis-
tered to the subject may vary. Oral, time release, intrave-
nous, intradermal, and other forms of administration are 
contemplated, as is topical administration. 
Topical administration refers to the application of a nico- 30 
tinic acid ester to the external surface of the skin or the 
alleviate or to prevent said side effect, to a subject for at least 
one month prior to said subject receiving, or while said 
subject is receiving, said retinoic acid. 
mucous membranes (including the surface membranes of the 
nose, lungs and mouth), such that the nicotinic acid ester 
crosses the external surface of the skin or mucous membrane 
and enters the underlying tissues. In the preferred form, the 
nicotinic acid ester is applied topically for dermal or trans-
dermal delivery of nicotinic acid. Transdermal delivery 
refers to the diffusion of a nicotinic acid ester across the 
barrier of the skin after which it is bioconverted to nicotinic 
acid by skin esterases. Absorption through intact skin can be 
enhanced by placing the nicotinic acid ester in an oily 
vehicle before application to the skin (a process known as 
inunction). Passive topical administration may consist of 
applying the nicotinic acid ester directly to the treatment site 
in combination with emollients or penetration enhancers. 
Such topical administration is particularly preferred and 
may be via a cream, lotion, liquid, aerosol, body wash, 
mouthwash, toothpaste, gavage, or other form of topical 
2. The method of claim 1 wherein said nicotinic acid alkyl 
ester is administered topically. 
35 3. The method of claim 1, wherein said nicotinic acid 
alkyl ester is administered by dermal or transdermal deliv-
ery. 
4. The method of claim 1, comprising administering said 
nicotinic acid alkyl ester concurrently with said retinoic 
40 acid. 
5. The method of claim 1, further comprising administer-
ing said nicotinic acid alkyl ester to said subject for at least 
one month prior to administration of said retinoic acid. 
6. The method of claim 1, wherein said subject is a 
45 mammal. 
7. The method of claim 6 wherein said mammal is a 
human. 
* * * * * 
